No impact of disease duration on response to tildrakizumab treatment among patients with moderate-to-severe plaque psoriasis: Post hoc analyses from two phase 3 (reSURFACE 1 and reSURFACE 2) and one phase 4 (TRIBUTE) studies.

Griss, Johannes; Ratzinger, Gudrun; Maul, Julia-Tatjana; Weger, Wolfgang; Thaçi, Diamant; Carrascosa, José Manuel; Jonak, Constanze

Griss, Johannes; Ratzinger, Gudrun; Maul, Julia-Tatjana; Weger, Wolfgang; Thaçi, Diamant; Carrascosa, José Manuel; Jonak, Constanze.

Affiliation

Griss J; Department of Dermatology Medical University of Vienna Vienna Austria.
Ratzinger G; Department of Dermatology Medical University of Innsbruck Innsbruck Austria.
Maul JT; Department of Dermatology University Hospital Zurich Zurich Switzerland.
Weger W; Faculty of Medicine University of Zurich Zurich Switzerland.
Thaçi D; Department of Dermatology and Venereology Medical University of Graz Graz Austria.
Carrascosa JM; Institute and Comprehensive Centre for Inflammation Medicine University of Lübeck Lübeck Germany.
Jonak C; Department of Dermatology Hospital Universitari Germans Trias i Pujol, IGTP, UAB Badalona Spain.

Skin Health Dis ; 3(5): e263, 2023 Oct.

Article de En | MEDLINE | ID: mdl-37799374

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Langue: En Journal: Skin Health Dis Année: 2023 Type de document: Article Pays de publication: Royaume-Uni

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google